Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13484794 | 0.94 | PLA2G2A (0.84) | PLA2G2A | |
| SCHEMBL7965081 | 0.93 | PLA2G2A (0.86) | PLA2G2APLA2G1B | |
| SCHEMBL7952696 | 0.91 | PLA2G2A (1.00) | PLA2G2A | |
| SCHEMBL7953360 | 0.90 | PLA2G2A (1.00) | PLA2G2APLA2G1B | |
| SCHEMBL7953342 | 0.90 | PLA2G2A (0.86) | PLA2G2APLA2G1B | |
| SCHEMBL24353497 | 0.89 | PLA2G2A (0.85) | PLA2G2A | |
| SCHEMBL7964131 | 0.89 | PLA2G2A (1.00) | PLA2G2A | |
| SCHEMBL7953243 | 0.89 | PLA2G2A (1.00) | PLA2G2APLA2G1B | |
| SCHEMBL7952631 | 0.89 | PLA2G2A (1.00) | PLA2G2A | |
| SCHEMBL7953805 | 0.88 | PLA2G2A (0.81) | PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6252084-B1 | THERAPY FOR SEPSIS SHOCK | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0620215-B1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | LILLY CO ELI (US) | 1999-08-18 | — | — | EP | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |